GDTC
CytoMed Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · SG
$0.85
−3.17%Next report
Analyst consensus
- Next report date
- Nov 13, 2026
- EPS estimate
- —
- Revenue estimate
- $126.9K
Latest reported
- Last report date
- Sep 30, 2025
- EPS actual
- -$0.07
- EPS estimate
- —
- Revenue actual
- $105.7K
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- —
- EPS misses (12Q)
- —
- EPS in line (12Q)
- —
- Avg surprise (4Q)
- —
- Revenue beats (12Q)
- —
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Sep 30, 2025 | — | -$0.07 | — | $105.7K |
| Mar 31, 2025 | — | -$0.05 | — | $74.3K |
| Sep 30, 2024 | — | -$0.04 | — | $83.3K |
| Jun 29, 2024 | — | -$0.05 | — | $61.0K |
| Mar 31, 2024 | — | -$0.03 | — | $61.4K |
| Sep 29, 2023 | — | -$0.05 | — | $59.7K |
| May 1, 2023 | — | -$0.10 | — | $80.2K |
| Sep 29, 2022 | — | -$0.06 | — | $70.2K |
| Jun 30, 2022 | — | -$0.07 | — | — |
| Mar 31, 2022 | — | -$0.04 | — | $20.3K |
| Dec 31, 2021 | — | -$0.08 | — | — |
| Sep 30, 2021 | — | -$0.04 | — | $23.1K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of May 3, 2027